Cargando…

Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia

Lung transplantation is a lifesaving therapy for people living with severe, life-threatening lung disease. The high mortality rate among patients awaiting transplantation is mainly due to the low percentage of lungs that are deemed acceptable for implantation. Thus, the current shortage of lung dono...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacienza, Natalia, Santa-Cruz, Diego, Malvicini, Ricardo, Robledo, Oscar, Lemus-Larralde, Gastón, Bertolotti, Alejandro, Marcos, Martín, Yannarelli, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701419/
https://www.ncbi.nlm.nih.gov/pubmed/31481974
http://dx.doi.org/10.1155/2019/8089215
_version_ 1783445054973542400
author Pacienza, Natalia
Santa-Cruz, Diego
Malvicini, Ricardo
Robledo, Oscar
Lemus-Larralde, Gastón
Bertolotti, Alejandro
Marcos, Martín
Yannarelli, Gustavo
author_facet Pacienza, Natalia
Santa-Cruz, Diego
Malvicini, Ricardo
Robledo, Oscar
Lemus-Larralde, Gastón
Bertolotti, Alejandro
Marcos, Martín
Yannarelli, Gustavo
author_sort Pacienza, Natalia
collection PubMed
description Lung transplantation is a lifesaving therapy for people living with severe, life-threatening lung disease. The high mortality rate among patients awaiting transplantation is mainly due to the low percentage of lungs that are deemed acceptable for implantation. Thus, the current shortage of lung donors may be significantly reduced by implementing different therapeutic strategies which facilitate both organ preservation and recovery. Here, we studied whether the anti-inflammatory effect of human umbilical cord-derived mesenchymal stem cells (HUCPVCs) increases lung availability by improving organ preservation. We developed a lung preservation rat model that mimics the different stages by which donor organs must undergo before implantation. The therapeutic schema was as follows: cardiac arrest, warm ischemia (2 h at room temperature), cold ischemia (1.5 h at 4°C, with Perfadex), and normothermic lung perfusion with ventilation (Steen solution, 1 h). After 1 h of warm ischemia, HUCPVCs (1 × 10(6) cells) or vehicle was infused via the pulmonary artery. Physiologic data (pressure-volume curves) were acquired right after the cardiac arrest and at the end of the perfusion. Interestingly, although lung edema did not change among groups, lung compliance dropped to 34% in the HUCPVC-treated group, while the vehicle group showed a stronger reduction (69%, p < 0.0001). Histologic assessment demonstrated less overall inflammation in the HUCPVC-treated lungs. In addition, MPO activity, a neutrophil marker, was reduced by 41% compared with vehicle (p < 0.01). MSC therapy significantly decreased tissue oxidative damage by controlling reactive oxygen species production. Accordingly, catalase and superoxide dismutase enzyme activities remained at baseline levels. In conclusion, these results demonstrate that the anti-inflammatory effect of MSCs protects donor lungs against ischemic injury and postulates MSC therapy as a novel tool for organ preservation.
format Online
Article
Text
id pubmed-6701419
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-67014192019-09-03 Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia Pacienza, Natalia Santa-Cruz, Diego Malvicini, Ricardo Robledo, Oscar Lemus-Larralde, Gastón Bertolotti, Alejandro Marcos, Martín Yannarelli, Gustavo Stem Cells Int Research Article Lung transplantation is a lifesaving therapy for people living with severe, life-threatening lung disease. The high mortality rate among patients awaiting transplantation is mainly due to the low percentage of lungs that are deemed acceptable for implantation. Thus, the current shortage of lung donors may be significantly reduced by implementing different therapeutic strategies which facilitate both organ preservation and recovery. Here, we studied whether the anti-inflammatory effect of human umbilical cord-derived mesenchymal stem cells (HUCPVCs) increases lung availability by improving organ preservation. We developed a lung preservation rat model that mimics the different stages by which donor organs must undergo before implantation. The therapeutic schema was as follows: cardiac arrest, warm ischemia (2 h at room temperature), cold ischemia (1.5 h at 4°C, with Perfadex), and normothermic lung perfusion with ventilation (Steen solution, 1 h). After 1 h of warm ischemia, HUCPVCs (1 × 10(6) cells) or vehicle was infused via the pulmonary artery. Physiologic data (pressure-volume curves) were acquired right after the cardiac arrest and at the end of the perfusion. Interestingly, although lung edema did not change among groups, lung compliance dropped to 34% in the HUCPVC-treated group, while the vehicle group showed a stronger reduction (69%, p < 0.0001). Histologic assessment demonstrated less overall inflammation in the HUCPVC-treated lungs. In addition, MPO activity, a neutrophil marker, was reduced by 41% compared with vehicle (p < 0.01). MSC therapy significantly decreased tissue oxidative damage by controlling reactive oxygen species production. Accordingly, catalase and superoxide dismutase enzyme activities remained at baseline levels. In conclusion, these results demonstrate that the anti-inflammatory effect of MSCs protects donor lungs against ischemic injury and postulates MSC therapy as a novel tool for organ preservation. Hindawi 2019-08-05 /pmc/articles/PMC6701419/ /pubmed/31481974 http://dx.doi.org/10.1155/2019/8089215 Text en Copyright © 2019 Natalia Pacienza et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pacienza, Natalia
Santa-Cruz, Diego
Malvicini, Ricardo
Robledo, Oscar
Lemus-Larralde, Gastón
Bertolotti, Alejandro
Marcos, Martín
Yannarelli, Gustavo
Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
title Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
title_full Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
title_fullStr Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
title_full_unstemmed Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
title_short Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
title_sort mesenchymal stem cell therapy facilitates donor lung preservation by reducing oxidative damage during ischemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701419/
https://www.ncbi.nlm.nih.gov/pubmed/31481974
http://dx.doi.org/10.1155/2019/8089215
work_keys_str_mv AT pacienzanatalia mesenchymalstemcelltherapyfacilitatesdonorlungpreservationbyreducingoxidativedamageduringischemia
AT santacruzdiego mesenchymalstemcelltherapyfacilitatesdonorlungpreservationbyreducingoxidativedamageduringischemia
AT malviciniricardo mesenchymalstemcelltherapyfacilitatesdonorlungpreservationbyreducingoxidativedamageduringischemia
AT robledooscar mesenchymalstemcelltherapyfacilitatesdonorlungpreservationbyreducingoxidativedamageduringischemia
AT lemuslarraldegaston mesenchymalstemcelltherapyfacilitatesdonorlungpreservationbyreducingoxidativedamageduringischemia
AT bertolottialejandro mesenchymalstemcelltherapyfacilitatesdonorlungpreservationbyreducingoxidativedamageduringischemia
AT marcosmartin mesenchymalstemcelltherapyfacilitatesdonorlungpreservationbyreducingoxidativedamageduringischemia
AT yannarelligustavo mesenchymalstemcelltherapyfacilitatesdonorlungpreservationbyreducingoxidativedamageduringischemia